Abstract
Here, two new cyclometallated iridium(III) complexes, [Ir(BrQ)(L1)2] (Ir-1) and [Ir(BrQ)(L2)2] (Ir-2) containing 5-bromo-8-quinolinol (H-BrQ), 2-phenylpyridine (H-L1) and 1-phenylpyrazole (H-L2) ligands have been explored as an anticancer agents targeting mitochondria. The cyclometallated iridium(III) complexes Ir-1 and Ir-2 exhibits excellent antineoplastic activity and promising selectivity towards cervical carcinoma HeLa, with IC50 values were 3.53 ± 0.44 μM and 0.50 ± 0.39 μM, as compared to the human HL-7702 healthy cells and cisplatin-resistant SK-OV-3/DDP cancer cells. Flow cytometry confirmed that cervical carcinoma HeLa cells were caused apoptosis after being treatment with Ir-1 and Ir-2. Along with the decrease of mitochondrial membrane potential (MMP) level, massive release of cytochrome c (cyto C), clear changes in apoptosis-associated proteins, and triggers caspase-mediated mitochondrial dysfunction apoptosis pathways.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
